wikidoc - Changes related to "Category:Emergency medicine" [en]

Aortic regurgitation overview

2026-05-08T23:56:28Z

Overview

Show changes

Heart failure resident survival guide

2026-05-06T22:22:38Z

Show changes

Congestive heart failure Management of Acute heart failure

2026-05-06T22:03:50Z

Show changes

Sandbox

2026-05-04T16:09:28Z

ACEI / ARB

Show changes

Sandbox

2026-04-29T10:11:34Z

Replaced content with "== '''Thoracic Aortic Aneurysm Medical Therapy''' == <references />"

Show changes

Thoracic aortic aneurysm medical therapy

2026-04-29T10:10:34Z

Medical Therapy

Show changes

Sandbox

2026-04-28T01:40:03Z

Show changes

Supraventricular tachycardia

2026-04-27T17:08:57Z

Show changes

Chronic stable angina overview

2026-04-25T15:44:25Z

Treatment

Show changes

Sandbox

2026-04-23T00:19:19Z

Medical Treatment of Patients With Thoracic Aortic Disease

← Older revision		Revision as of 00:19, 23 April 2026
(2 intermediate revisions by the same user not shown)
Line 35:		Line 35:
	{\| class="wikitable"		{\| class="wikitable"
	\|-		\|-
	\|[[ACC AHA guidelines classification scheme#Classification of Recommendations\|Class I]]		\|colspan="1" style="text-align:center; background:LightGreen"\|[[ACC AHA guidelines classification scheme#Classification of Recommendations\|Class I]]
	\|-		\|-
	\|"'''1.''' Stringent control of ~~<nowiki>~~[[hypertension]]~~</nowiki>~~, ~~<nowiki>~~[[lipid profile]]~~</nowiki>~~ optimization, <nowiki>[[smoking cessation]]</nowiki>, and other <nowiki>[[atherosclerosis]]</nowiki> risk-reduction measures should be instituted for all patients with <nowiki>[[thoracic aortic aneurysm]]</nowiki> not requiring immediate surgical intervention, as well as for patients who are not considered surgical or stent graft candidates. ''([[ACC AHA guidelines classification scheme#Level of Evidence\|Level of Evidence: C]])''"		\|colspan="1" style="text-align:center; background:LightGreen"\|'''1.''' Stringent control of [[hypertension]], [[lipid profile]] optimization, <nowiki>[[smoking cessation]]</nowiki>, and other <nowiki>[[atherosclerosis]]</nowiki> risk-reduction measures should be instituted for all patients with <nowiki>[[thoracic aortic aneurysm]]</nowiki> not requiring immediate surgical intervention, as well as for patients who are not considered surgical or stent graft candidates. ''([[ACC AHA guidelines classification scheme#Level of Evidence\|Level of Evidence: C]])''"
	\|}		\|}

Sandbox

2026-04-22T17:31:17Z

Thoracic Aortic Aneurysm Medical Therapy ===== Overview ===Medical therapy for patients with a thoracic aortic aneurysm includes aggressive blood pressure control targeting a goal of 130/80 mmHg for all patients, heart rate reduction with beta-

Show changes

Heart failure resident survival guide

2026-04-21T11:24:22Z

Treatment of Heart Failure in Stage C and D

Show changes

Congestive heart failure Management of Acute heart failure

2026-04-18T10:39:34Z

Transitional care plan: components (Class 1 recommendation):[2]

Show changes

Sandbox

2026-04-16T00:52:30Z

← Older revision		Revision as of 00:52, 16 April 2026
Line 1:		Line 1:
			== ACS Treatment ==
			Primary Prevention:

	~~{{familytree/start}}~~		'''Equivalent intensity for CHD-risk equivalents (LoE: A):''' Patients with established CHD should be targeted for secondary prevention. Crucially, patients with a '''CHD risk equivalent''' — defined as atherosclerosis in other vascular beds, diabetes mellitus, chronic kidney disease, or a Framingham-calculated 10-year risk exceeding 20% — should receive '''the same intensity of risk factor intervention''' as those with overt, clinically apparent CHD.
	~~{{familytree \| \| \| \| \| \| \| \| \| \| \| \| A01 \| \| \| \| \| \|A01=Adult ALL }}~~
	~~{{familytree \| \|,\|-\|-\|-\|v\|-\|-\|-\|-\|-\|-\|+\|-\|-\|-\|-\|-\|-\|-\|-\|-\|.\| \| }}~~
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \| \| \| \|!\| \| \| \| \| \| \| \| \| \|!\| \| \| }}~~
	~~{{familytree \| D01 \| \| D02 \| \| \| \| \| D03 \| \| \| \| \| \| \| \| D05 \| \| \| \|D01=Burkitt Leukemia\|D02=PH-Positive B-ALL\|D03=PH-negative B-ALL\|D05=T-ALL}}~~
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|,\|-\|-\|^\|-\|-\|.\| \| \| \|,\|-\|-\|^\|-\|-\|.\| \| \| }}~~
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| }}~~
	{{familytree \| E01 \| \| E02 \| \| E03 \| \| \| \| E04 \| \| E05 \| \| \| \| E06 \| \| \|E01=R-hyper CVAD<br> DA-R-EPOCH\|E02=Chemotherapt+TKI <br> Blinatumomab+TKI\|E03=Younger adults\|E04=Older Adults\|E05=ETP\|E06=Non ETP}}
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \|}}~~
	{{familytree \| \|!\| \| \| \|!\| \| \| F01 \| \| \| \| F02 \| \| F03 \| \| \| \| F04 \| \|F01=Chemotherapy+<br>blinatumomab\|F02=Chemotherapy+<br>blinatumumab+InO <br>Chemotherapy-free blinatumomab + InO\|F03=Chemotherapy+pegAsp+<br>nelarabine+venetoclax\|F04=Chemotherapy+pegAsp+<br>nelarabine}}
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| }}~~
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| }}~~
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| }}~~
	~~{{familytree \| \|`\|-\|-\|-\|^\|-\|-\|-\|^\|-\|-\|v\|-\|-\|^\|-\|-\|-\|^\|-\|-\|-\|-\|-\|~~'~~\| \| \| }}~~
	~~{{familytree \| \| \| \| \| \| \| \| \| \| \| \| G01 \| \| \| \| \| \| \| \| \| \| \| \| \| \|G01=<div style="float: left; text~~-~~align~~: ~~left; height~~: ~~3em; width: 20em;">~~ '''~~Measurable residual disease monitoring~~'''~~<br> </div>}} }}~~
	~~{{familytree \| \| \| \| \| \| \| \| \| \| \| \| \|!\| \| \| \| \| \| \| \| \| \| \| \| \| \| }}~~
	~~{{familytree \| \| \| \| \| \| \| \| \| \| \| \| H01 \| \| \| \| \| \| \| \| \| \| \| \| \| \| \|H01=<div style="float: left; text~~-~~align: left;">~~'''~~Alloegenic hematopoietic stem cell transplant~~''' ~~<br>•Ph-like ALL~~ with ~~CRLF2 and JAK vairants<br>•High-risk cytogenetics in B-ALL<br>•High-risk Ph-positive B-ALL: IZKF1 genotype<br>•T-ALL: ETP-ALL<br>•Persistent measurable residual disease by NGS<br> </div>}}~~
	~~{{familytree/end}}~~

Low back pain conservative management

2026-04-14T16:24:46Z

Physical Therapy

← Older revision		Revision as of 16:24, 14 April 2026
Line 17:		Line 17:
	The Mckenzie Method has been shown to be a modestly effective therapy for adults with chronic low back pain. A 2011 summary of 4 studies showed consistent significant improvement in pain and function although only one study had a large enough population to demonstrate effect sizes on pain and functional outcomes, 0.50 and 0.39 respectively.<ref name="pmid22135496">{{cite journal\| author=Dunsford A, Kumar S, Clarke S\| title=Integrating evidence into practice: use of McKenzie-based treatment for mechanical low back pain. \| journal=J Multidiscip Healthc \| year= 2011 \| volume= 4 \| issue= \| pages= 393-402 \| pmid=22135496 \| doi=10.2147/JMDH.S24733 \| pmc=PMC3215349 \| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22135496 }} </ref>		The Mckenzie Method has been shown to be a modestly effective therapy for adults with chronic low back pain. A 2011 summary of 4 studies showed consistent significant improvement in pain and function although only one study had a large enough population to demonstrate effect sizes on pain and functional outcomes, 0.50 and 0.39 respectively.<ref name="pmid22135496">{{cite journal\| author=Dunsford A, Kumar S, Clarke S\| title=Integrating evidence into practice: use of McKenzie-based treatment for mechanical low back pain. \| journal=J Multidiscip Healthc \| year= 2011 \| volume= 4 \| issue= \| pages= 393-402 \| pmid=22135496 \| doi=10.2147/JMDH.S24733 \| pmc=PMC3215349 \| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22135496 }} </ref>

	A randomized controlled ~~trail~~ in 2015 found minimal benefit.<ref name="v851">{{cite journal \| last1=Fritz \| first1=Julie M. \| last2=Magel \| first2=John S. \| last3=McFadden \| first3=Molly \| last4=Asche \| first4=Carl \| last5=Thackeray \| first5=Anne \| last6=Meier \| first6=Whitney \| last7=Brennan \| first7=Gerard \| title=Early Physical Therapy vs Usual Care in Patients With Recent-Onset Low Back Pain: A Randomized Clinical Trial \| journal=JAMA \| volume=314 \| issue=14 \| date=2015-10-13 \| issn=0098-7484 \| doi=10.1001/jama.2015.11648 \| page=1459 \| url=http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2015.11648 \| access-date=2026-04-12}}</ref>		A [[randomized controlled trial]] in 2015 found minimal benefit.<ref name="v851">{{cite journal \| last1=Fritz \| first1=Julie M. \| last2=Magel \| first2=John S. \| last3=McFadden \| first3=Molly \| last4=Asche \| first4=Carl \| last5=Thackeray \| first5=Anne \| last6=Meier \| first6=Whitney \| last7=Brennan \| first7=Gerard \| title=Early Physical Therapy vs Usual Care in Patients With Recent-Onset Low Back Pain: A Randomized Clinical Trial \| journal=JAMA \| volume=314 \| issue=14 \| date=2015-10-13 \| issn=0098-7484 \| doi=10.1001/jama.2015.11648 \| pmid = 26461996 \| page=1459 \| url=http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2015.11648 \| access-date=2026-04-12}}</ref> Outcomes were measured with the Oswestry Disability Index (ODI: range 0 to 100) which has a recommended minimum clinically important difference (MCID) of 6<ref name="pmid11175676">{{cite journal \| last1=Fritz \| first1=J. M. \| last2=Irrgang \| first2=J. J. \| title=A comparison of a modified Oswestry Low Back Pain Disability Questionnaire and the Quebec Back Pain Disability Scale \| journal=Physical Therapy \| volume=81 \| issue=2 \| date=2001 \| issn=0031-9023 \| pmid=11175676 \| doi=10.1093/ptj/81.2.776 \| pages=776–788 \| url=https://pubmed.gov/11175676 \| access-date=2026-04-14}}</ref>. While both the intervention and usual care group had improvement well above the MCID, the "Mean Difference Between Groups in Change from Baseline" were less than 4 at all time points.

	===Pilates===		===Pilates===

← Older revision		Revision as of 00:52, 16 April 2026
Line 1:		Line 1:
			== ACS Treatment ==
			Primary Prevention:

	~~{{familytree/start}}~~		'''Equivalent intensity for CHD-risk equivalents (LoE: A):''' Patients with established CHD should be targeted for secondary prevention. Crucially, patients with a '''CHD risk equivalent''' — defined as atherosclerosis in other vascular beds, diabetes mellitus, chronic kidney disease, or a Framingham-calculated 10-year risk exceeding 20% — should receive '''the same intensity of risk factor intervention''' as those with overt, clinically apparent CHD.
	~~{{familytree \| \| \| \| \| \| \| \| \| \| \| \| A01 \| \| \| \| \| \|A01=Adult ALL }}~~
	~~{{familytree \| \|,\|-\|-\|-\|v\|-\|-\|-\|-\|-\|-\|+\|-\|-\|-\|-\|-\|-\|-\|-\|-\|.\| \| }}~~
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \| \| \| \|!\| \| \| \| \| \| \| \| \| \|!\| \| \| }}~~
	~~{{familytree \| D01 \| \| D02 \| \| \| \| \| D03 \| \| \| \| \| \| \| \| D05 \| \| \| \|D01=Burkitt Leukemia\|D02=PH-Positive B-ALL\|D03=PH-negative B-ALL\|D05=T-ALL}}~~
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|,\|-\|-\|^\|-\|-\|.\| \| \| \|,\|-\|-\|^\|-\|-\|.\| \| \| }}~~
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| }}~~
	{{familytree \| E01 \| \| E02 \| \| E03 \| \| \| \| E04 \| \| E05 \| \| \| \| E06 \| \| \|E01=R-hyper CVAD<br> DA-R-EPOCH\|E02=Chemotherapt+TKI <br> Blinatumomab+TKI\|E03=Younger adults\|E04=Older Adults\|E05=ETP\|E06=Non ETP}}
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \|}}~~
	{{familytree \| \|!\| \| \| \|!\| \| \| F01 \| \| \| \| F02 \| \| F03 \| \| \| \| F04 \| \|F01=Chemotherapy+<br>blinatumomab\|F02=Chemotherapy+<br>blinatumumab+InO <br>Chemotherapy-free blinatumomab + InO\|F03=Chemotherapy+pegAsp+<br>nelarabine+venetoclax\|F04=Chemotherapy+pegAsp+<br>nelarabine}}
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| }}~~
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| }}~~
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| }}~~
	~~{{familytree \| \|`\|-\|-\|-\|^\|-\|-\|-\|^\|-\|-\|v\|-\|-\|^\|-\|-\|-\|^\|-\|-\|-\|-\|-\|~~'~~\| \| \| }}~~
	~~{{familytree \| \| \| \| \| \| \| \| \| \| \| \| G01 \| \| \| \| \| \| \| \| \| \| \| \| \| \|G01=<div style="float: left; text~~-~~align~~: ~~left; height~~: ~~3em; width: 20em;">~~ '''~~Measurable residual disease monitoring~~'''~~<br> </div>}} }}~~
	~~{{familytree \| \| \| \| \| \| \| \| \| \| \| \| \|!\| \| \| \| \| \| \| \| \| \| \| \| \| \| }}~~
	~~{{familytree \| \| \| \| \| \| \| \| \| \| \| \| H01 \| \| \| \| \| \| \| \| \| \| \| \| \| \| \|H01=<div style="float: left; text~~-~~align: left;">~~'''~~Alloegenic hematopoietic stem cell transplant~~''' ~~<br>•Ph-like ALL~~ with ~~CRLF2 and JAK vairants<br>•High-risk cytogenetics in B-ALL<br>•High-risk Ph-positive B-ALL: IZKF1 genotype<br>•T-ALL: ETP-ALL<br>•Persistent measurable residual disease by NGS<br> </div>}}~~
	~~{{familytree/end}}~~